{"?xml":{"@version":"1.0"},"edm:RDF":{"@xmlns:dc":"http://purl.org/dc/elements/1.1/","@xmlns:edm":"http://www.europeana.eu/schemas/edm/","@xmlns:wgs84_pos":"http://www.w3.org/2003/01/geo/wgs84_pos","@xmlns:foaf":"http://xmlns.com/foaf/0.1/","@xmlns:rdaGr2":"http://rdvocab.info/ElementsGr2","@xmlns:oai":"http://www.openarchives.org/OAI/2.0/","@xmlns:owl":"http://www.w3.org/2002/07/owl#","@xmlns:rdf":"http://www.w3.org/1999/02/22-rdf-syntax-ns#","@xmlns:ore":"http://www.openarchives.org/ore/terms/","@xmlns:skos":"http://www.w3.org/2004/02/skos/core#","@xmlns:dcterms":"http://purl.org/dc/terms/","edm:WebResource":[{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-K0TJLOQE/7e758b46-bcf1-4ffd-bcae-0ffbe35e822b/HTML","dcterms:extent":"31 KB"},{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-K0TJLOQE/82054d1b-6e89-42d9-bd2f-dcaa6de9064b/PDF","dcterms:extent":"161 KB"},{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-K0TJLOQE/9ee27b49-594a-4fb4-924c-049fbf94db41/TEXT","dcterms:extent":"30 KB"}],"edm:TimeSpan":{"@rdf:about":"1929-2026","edm:begin":{"@xml:lang":"en","#text":"1929"},"edm:end":{"@xml:lang":"en","#text":"2026"}},"edm:ProvidedCHO":{"@rdf:about":"URN:NBN:SI:doc-K0TJLOQE","dcterms:isPartOf":[{"@rdf:resource":"https://www.dlib.si/details/urn:nbn:si:spr-a30mfzkp"},{"@xml:lang":"sl","#text":"Zdravniški vestnik"}],"dcterms:issued":"2005","dc:creator":"Mavri, Alenka","dc:format":[{"@xml:lang":"sl","#text":"številka:6"},{"@xml:lang":"sl","#text":"letnik:74"},{"@xml:lang":"sl","#text":"str. 375-379"}],"dc:identifier":["ISSN:1318-0347","COBISSID:19576537","URN:URN:NBN:SI:doc-K0TJLOQE"],"dc:language":"sl","dc:publisher":{"@xml:lang":"sl","#text":"Slovensko zdravniško društvo"},"dc:subject":[{"@xml:lang":"sl","#text":"ateroskleroza"},{"@xml:lang":"en","#text":"Atherosclerosis"},{"@xml:lang":"sl","#text":"Debelost"},{"@xml:lang":"en","#text":"Diabetes Mellitus, Non-Insulin-Dependent"},{"@xml:lang":"sl","#text":"Hiperinzulinemija"},{"@xml:lang":"sl","#text":"Hiperlipidemija"},{"@xml:lang":"sl","#text":"Hipertenzija"},{"@xml:lang":"en","#text":"Hyperinsulinemia"},{"@xml:lang":"en","#text":"Hyperlipidemia"},{"@xml:lang":"en","#text":"Hypertension"},{"@xml:lang":"en","#text":"insulin"},{"@xml:lang":"en","#text":"Insulin Resistance"},{"@xml:lang":"sl","#text":"Insulinska rezistenca"},{"@xml:lang":"sl","#text":"metabolizem"},{"@xml:lang":"en","#text":"Obesity"},{"@xml:lang":"en","#text":"Plasminogen Activator Inhibitor 1"},{"@xml:lang":"sl","#text":"Plazminogen aktivator, inhibitor 1"},{"@xml:lang":"sl","#text":"presnovne motnje"},{"@xml:lang":"sl","#text":"Sladkorna bolezen, ne-inzulin-odvisna"}],"dcterms:temporal":{"@rdf:resource":"1929-2026"},"dc:title":{"@xml:lang":"sl","#text":"Povezava med metabolnim sindromom, inhibitorjem aktivatorja plazminogena (PAI-1) in aterosklerozo| Metabolic syndrome, plasminogen activator inhibitor (PAI-1) and atherosclerosis|"},"dc:description":[{"@xml:lang":"sl","#text":"Background. Metabolic syndrome is associated with high cardiovascular morbidity and mortality and its increasing prevalence is becoming one of the major health problems. Atherothrombotic process is accelerated in the metabolic syndrome and this is attributed to metabolic abnormalities, hypofibrinolysis due to increased plasma PAI-1 levels, and inflammation. Proinflammatory cytokines, particularly tumour necrosis factor-a may have an important role in PAI-1 overexpresion in the adipose tissue. PAI-1 might be involved in the etiopathogenesis of obesity and insulin resistance. Conclusions. To understand a complex interplay between metabolic syndrome, PAi-1 and atherosclerosis further studies are needed"},{"@xml:lang":"sl","#text":"Izhodišča. Prevalenca metabolnega sindroma v razvitem svetu strmo narašča, karje velik zdravstveni problem, saj metabolni sindrom spremlja visoka stopnjasrčnožilne obolevnosti in umrljivosti. Na pospešen proces aterotrombozepri ljudeh z metabolnim sindromom vplivajo presnovne motnje, hipofibrinoliza zaradi zvečane ravni inhibitorja aktivatorja plazminogena (PAI-1) in kronično subklinično vnetje. Vnetni citokini, predvsem dejavnik tumorske nekroze-a, se vpletajo v uravnavanje tvorbe PAI-1 v maščevju. PAI-1 je lahko eden pomembnejših etiopatogenetskih dejavnikov tako za debelost kot tudi za neodzivnost na insulin. Zaključki. Za dokončno razjasnitev povezav medmetabolnim sindromom, PAI-1 in aterosklerozo bodo potrebne še številne raziskave, predvsem intervencijske"}],"edm:type":"TEXT","dc:type":[{"@xml:lang":"sl","#text":"znanstveno časopisje"},{"@xml:lang":"en","#text":"journals"},{"@rdf:resource":"http://www.wikidata.org/entity/Q361785"}]},"ore:Aggregation":{"@rdf:about":"http://www.dlib.si/?URN=URN:NBN:SI:doc-K0TJLOQE","edm:aggregatedCHO":{"@rdf:resource":"URN:NBN:SI:doc-K0TJLOQE"},"edm:isShownBy":{"@rdf:resource":"http://www.dlib.si/stream/URN:NBN:SI:doc-K0TJLOQE/82054d1b-6e89-42d9-bd2f-dcaa6de9064b/PDF"},"edm:rights":{"@rdf:resource":"http://creativecommons.org/licenses/by-nc/4.0/"},"edm:provider":"Slovenian National E-content Aggregator","edm:intermediateProvider":{"@xml:lang":"en","#text":"National and University Library of Slovenia"},"edm:dataProvider":{"@xml:lang":"sl","#text":"Slovensko zdravniško društvo"},"edm:object":{"@rdf:resource":"http://www.dlib.si/streamdb/URN:NBN:SI:doc-K0TJLOQE/maxi/edm"},"edm:isShownAt":{"@rdf:resource":"http://www.dlib.si/details/URN:NBN:SI:doc-K0TJLOQE"}}}}